Gene: NRG3

10718
HRG3|pro-NRG3
neuregulin 3
protein-coding
10q23.1
Ensembl:ENSG00000185737 MIM:605533 Vega:OTTHUMG00000018626 UniprotKB:P56975
NG_013373.1
PubMed|SNP Mapped
1   ANCO-SNPs
ND|AD
6   
NA (AD)  NA (ND)   (Frontal_Cortex)
1.380e-1 (AD)  7.613e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs1937970chr10:82463710 (GRCh38.p7)A>Galcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
NRXN10.952
PPM1L0.948
MAPK100.935
CDS10.935
ASTN10.925
KIAA03190.925
FAM155A0.925
KALRN0.924
OXCT10.923
AMIGO10.922

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CSAG1-0.51
RAI14-0.498
TFPI2-0.49
SH2D1A-0.489
OR4F5-0.486
SGMS2-0.475
HEY2-0.451
TGFB3-0.45
BEST3-0.448
FMO3-0.444

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of NRG3 mRNA"25510870
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of NRG3 mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of NRG3 mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of NRG3 mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of NRG3 mRNA"25510870
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRG3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRG3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRG3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRG3 mRNA"27188386
C016601afimoxifeneafimoxifene inhibits the reaction [Estrogens results in decreased expression of NRG3 mRNA]21233418
D001151ArsenicArsenic affects the expression of NRG3 protein24675094
C006632arsenic trioxidearsenic trioxide results in increased expression of NRG3 mRNA20458559
C006780bisphenol Abisphenol A results in decreased expression of NRG3 mRNA25181051
C054133casticincasticin results in decreased expression of NRG3 mRNA27862857
D004967Estrogensafimoxifene inhibits the reaction [Estrogens results in decreased expression of NRG3 mRNA]21233418
D004967EstrogensEstrogens results in decreased expression of NRG3 mRNA21233418
D007854LeadLead affects the expression of NRG3 mRNA28903495
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of NRG3 mRNA28001369
D009532NickelNickel results in decreased expression of NRG3 mRNA25583101
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of NRG3 mRNA"25510870
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRG3 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of NRG3 mRNA26272509
C012589trichostatin Atrichostatin A results in increased expression of NRG3 mRNA24935251
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRG3 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of NRG3 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of NRG3 mRNA23179753|2438349
D001335Vehicle EmissionsVehicle Emissions affects the methylation of NRG3 gene25560391

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005102signaling receptor binding-IBA21873635  
GO:0008083growth factor activity-NAS9275162  
GO:0030297transmembrane receptor protein tyrosine kinase activator activity-NAS9275162  
GO:0030971receptor tyrosine kinase binding-NAS9275162  
GO:0045499chemorepellent activity-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0001558regulation of cell growth-NAS9275162  
GO:0007171activation of transmembrane receptor protein tyrosine kinase activity-IEA-  
GO:0007389pattern specification process-IEA-  
GO:0010469regulation of signaling receptor activity-IEA-  
GO:0021842chemorepulsion involved in interneuron migration from the subpallium to the cortex-IEA-  
GO:0035556intracellular signal transduction-IBA21873635  
GO:0048513animal organ development-IBA21873635  
GO:0060596mammary placode formation-IEA-  
GO:2001223negative regulation of neuron migration-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005576extracellular region-NAS9275162  
GO:0005615extracellular space-IBA21873635  
GO:0005622intracellular-IEA-  
GO:0005887integral component of plasma membrane-NAS9275162  
KEGG ID KEGG Term
hsa04012ErbB signaling pathway
Reactome ID Reactome Term Evidence
R-HSA-1227986Signaling by ERBB2TAS
R-HSA-1227986Signaling by ERBB2IEA
R-HSA-1236394Signaling by ERBB4TAS
R-HSA-1236394Signaling by ERBB4IEA
R-HSA-1250196SHC1 events in ERBB2 signalingIEA
R-HSA-1250196SHC1 events in ERBB2 signalingTAS
R-HSA-1250342PI3K events in ERBB4 signalingTAS
R-HSA-1250347SHC1 events in ERBB4 signalingTAS
R-HSA-1251985Nuclear signaling by ERBB4IEA
R-HSA-1257604PIP3 activates AKT signalingTAS
R-HSA-162582Signal TransductionTAS
R-HSA-162582Signal TransductionIEA
R-HSA-1643685DiseaseTAS
R-HSA-1963640GRB2 events in ERBB2 signalingTAS
R-HSA-1963642PI3K events in ERBB2 signalingTAS
R-HSA-199418Negative regulation of the PI3K/AKT networkTAS
R-HSA-2219528PI3K/AKT Signaling in CancerTAS
R-HSA-2219530Constitutive Signaling by Aberrant PI3K in CancerTAS
R-HSA-5663202Diseases of signal transductionTAS
R-HSA-5673001RAF/MAP kinase cascadeTAS
R-HSA-5683057MAPK family signaling cascadesTAS
R-HSA-5684996MAPK1/MAPK3 signalingTAS
R-HSA-6785631ERBB2 Regulates Cell MotilityTAS
R-HSA-6811558PI5P, PP2A and IER3 Regulate PI3K/AKT SignalingTAS
R-HSA-8847993ERBB2 Activates PTK6 SignalingTAS
R-HSA-8848021Signaling by PTK6TAS
R-HSA-8863795Downregulation of ERBB2 signalingTAS
R-HSA-9006925Intracellular signaling by second messengersTAS
R-HSA-9006927Signaling by Non-Receptor Tyrosine KinasesTAS
R-HSA-9006934Signaling by Receptor Tyrosine KinasesTAS
R-HSA-9006934Signaling by Receptor Tyrosine KinasesIEA

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
23999525Evidence from mouse and man for a role of neuregulin 3 in nicotine dependence. (2014 Jul)Turner JRMol Psychiatry
22511924Genetic dissection of acute ethanol responsive gene networks in prefrontal cortex: functional and mechanistic implications. (2012)Wolen ARPLoS One
28892072Neuregulin signaling pathway in smoking behavior. (2017 Aug 22)Gupta RTransl Psychiatry
21546496Novel loci involved in platelet function and platelet count identified by a genome-wide study performed in children. (2011 Sep)Guerrero JAHaematologica
29114105Neuregulin 3 Signaling Mediates Nicotine-Dependent Synaptic Plasticity in the Orbitofrontal Cortex and Cognition. (2018 May)Zhou LNeuropsychopharmacology
23752247Genome-wide association study on detailed profiles of smoking behavior and nicotine dependence in a twin sample. (2014 May)Loukola AMol Psychiatry